Sprycel 70 mg film-coated tablets
Authorisation EU/1/06/363/3-6-9 · Bristol-Myers Squibb Pharma EEIG
- Licence holder
- Bristol-Myers Squibb Pharma EEIG (all products →)
- Active substance
- Dasatinib
- Clinical trials
- 30 clinical trials →
- Dosage form
- Film-coated tablet
- Route of administration
- Oral use
- ATC codes
- L01XE, L01XE06
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Dasatinib: supply and approvals
33 authorised products on the HPRA list contain Dasatinib. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 363. The HPRA list does not say whether it is on sale.
Other medicines with Dasatinib in Ireland
32 other products on the HPRA list contain Dasatinib, from 6 licence holders; 12 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Dasatinib Clonmel 100 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Dasatinib Clonmel 20 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Dasatinib Clonmel 50 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Dasatinib Clonmel 70 mg film-coated tablets | Clonmel Healthcare Ltd | National authorisation (PA) | Marketed |
| Dasatinib Teva 100 mg Film-coated Tablets | Teva B.V. | National authorisation (PA) | Marketed |
| Dasatinib Teva 20 mg Film-coated Tablets | Teva B.V. | National authorisation (PA) | Marketed |
| Dasatinib Teva 50 mg Film-coated Tablets | Teva B.V. | National authorisation (PA) | Marketed |
| Dasatinib Teva 70 mg Film-coated Tablets | Teva B.V. | National authorisation (PA) | Marketed |
| Mubucho 16 mg film-coated tablets | Zentiva k.s. | National authorisation (PA) | Marketed |
| Mubucho 40 mg film-coated tablets | Zentiva k.s. | National authorisation (PA) | Marketed |
| Mubucho 55 mg film-coated tablets | Zentiva k.s. | National authorisation (PA) | Marketed |
| Mubucho 79 mg film-coated tablets | Zentiva k.s. | National authorisation (PA) | Marketed |
Other substances in ATC group L01XE
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 29 other active substances share the group L01XE with this product:
Rad n bht (7) · Everolimus (6) · Imatinib mesilate (5) · Afatinib-dimaleate (4) · Imatinib (4) · Sunitinib malate (4) · Avapritinib (3) · Cabozantinib (3) · Ponatinib hci (3) · Nintedanib (3) · Pazopanib hydrochloride (3) · Sunitinib (3) · Nilotinib (3) · Vandetanib (2) · Cabozantinib (s)-malate (2) · Lenvatinib mesilate (2) · Selumetinib Sulfate (2) · Tivozanib (1) · Fedratinib dihydrochloride monohydrate (1) · Fedratinib (1) · and 9 more
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Bristol-Myers Squibb Pharma EEIG holds 55 products on the HPRA list, with 22 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.